Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.17 USD
Change Today +0.02 / 0.93%
Volume 77.3K
As of 5:20 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$2.14
Previous Close
$2.15
Day High
$2.20
Day Low
$2.06
52 Week High
09/2/14 - $19.80
52 Week Low
08/26/15 - $1.60
Market Cap
17.0M
Average Volume 10 Days
69.1K
EPS TTM
$-4.06
Shares Outstanding
7.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson’s disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University to develop its full thickness skin replacement product. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

10 Employees
Last Reported Date: 04/6/15
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $220.6K
Chief Financial Officer
Total Annual Compensation: $175.0K
Vice President of Financial Operations, Treas...
Total Annual Compensation: $138.3K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $126.0K
Compensation as of Fiscal Year 2014.

amarantus bioscience holding (AMBS) Key Developments

Amarantus Bioscience Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Amarantus Bioscience Holdings Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Net loss for the three months ended June 30, 2015 was $5,722,000 as compared to a net loss of $4,025,000 for the three month period ended June 30, 2014 with the increase in loss driven by research and development expense, consulting, Lonza Option payments, professional services and acquisition costs. Loss from operations was at $5,596,000 against $3,741,000 reported last year. Net loss attributable to common stockholders was $8,909,000 or $1.08 per basic and diluted share against $4,051,000 or $0.83 per basic and diluted share a year ago. Net loss for the six months ended June 30, 2015 was $12,302,000 as compared to a net loss of $9,567,000 for the six month period ended June 30, 2014 with the increase in loss driven by research and development expense, consulting, Lonza Option payments, professional services and acquisition costs. Loss from operations was at $12,134,000 against $5,377,000 reported last year. Net loss attributable to common stockholders was $16,318,000 or $2.13 per basic and diluted share against $9,619,000 or $0.02 per basic and diluted share a year ago.

Amarantus Bioscience Holdings, Inc Announces Resignation of Iain G. Ross as Member of the Board of Directors

On July 31, 2015, Iain G. Ross resigned as a member of the Board of Directors of Amarantus BioScience Holdings Inc., effective immediately, in order to devote his full time and attention to his new role as Acting CEO of Novogen Limited.

Amarantus Bioscience Holdings, Inc, Special/Extraordinary Shareholders Meeting, Aug 07, 2015

Amarantus Bioscience Holdings, Inc, Special/Extraordinary Shareholders Meeting, Aug 07, 2015., at 11:00 US Eastern Standard Time. Location: Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32 Floor.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $2.17 USD +0.02

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.